In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025.

The healthcare innovation landscape in 2025 is navigating a complex mix of challenges and opportunities, marked by contrasting trends in fundraising, investment, and technology adoption. In the first half of the year, U.S. healthcare venture capital (VC) fundraising totaled approximately $3 billion, representing a sharp decline and potentially the weakest year for healthcare fundraising in over a decade. This slowdown reflects macroeconomic pressures such as high interest rates, inflation concerns, geopolitical tensions, and policy uncertainties that impact funding and operations. Despite these headwinds, private healthcare markets remain resilient, with notable activity in biopharma mergers, acquisitions, and strategic licensing deals.

Artificial intelligence (AI) has emerged as a bright spot within the sector. Healthtech AI deal volume has nearly doubled since 2022, becoming a key driver of innovation funding. Digital health startups raised $6.4 billion in VC funding in the first half of 2025, up from $6 billion in the same period in 2024, fueled by investor interest in AI solutions that improve clinical decision support, imaging, and operational efficiency. Additionally, China has significantly increased its role in biopharma licensing, spending $3 billion on deals in H1 2025 alone, surpassing total 2024 spending, yet U.S. biopharma investment remains robust.

However, the broader healthcare sector faces substantial pressure. Mizuho healthcare strategist Jared Holz highlighted on CNBC’s “The Exchange” that the industry is under unprecedented strain, with large-cap pharmaceuticals and managed care bearing the brunt. He noted that healthcare has rarely outperformed the market in the past decade except during market downturns and described current conditions as the worst the sector has experienced in decades.

Despite these challenges, strategic acquisitions, early-stage investments, and a potential revival in IPO activity suggest the industry remains primed for innovation. AI-driven solutions are increasingly addressing longstanding inefficiencies, positioning healthcare for growth and transformation even amid funding headwinds. The sector stands at a pivotal crossroads, balancing economic pressures with technology-driven opportunities that could shape its future trajectory.

With these trends in mind, let’s now take a look at the most oversold healthcare stocks in 2025.

Our Methodology 

For our methodology, we first used Stock Analysis’s stock screener to filter for companies with a market capitalization above $2 billion and a Relative Strength Index (RSI) below 40. From this filtered list, we identified the stocks with the lowest RSI values and ranked them in descending order to select the top stocks.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 13 most oversold healthcare stocks so far in 2025. 

13. Perrigo Company plc (NYSE:PRGO)

Relative Strength Index (RSI): 35.21 

Perrigo Company plc (NYSE:PRGO), a global leader in consumer self-care products, is sharpening its focus on high-growth, high-margin categories across North America and Europe, and it stands thirteenth on our list among the most oversold stocks. Its portfolio spans pain and sleep aids, nutrition, digestive health, and oral care, with recent gains in OTC store brands signaling competitive strength despite challenging market conditions.

In Q2 2025, Perrigo Company plc (NYSE:PRGO) reported net sales of $1.06 billion, a 0.9% decline year-over-year, influenced by divestitures and exited products, particularly in infant formula and digestive health. The corporation continues to navigate soft seasonal demand in allergy, sun care, and blister care categories, as well as slower-than-expected recovery in infant formula.

Under its “Three-S” strategy—Stabilize, Streamline, and Strengthen- the firm is divesting non-core assets, including the Dermacosmetics business, expected to close in Q1 2026. This move aims to streamline operations, reinforce the balance sheet, accelerate debt reduction, and enable greater focus on its core self-care portfolio.

Operational enhancements, including a global operating model upgrade and strengthened brand-building capabilities, are already contributing to market share gains in key segments. Perrigo Company plc (NYSE:PRGO) is emphasizing innovation and expansion in pain and sleep aids, nutrition, and upper respiratory products, aligning resources with higher-growth categories.

12. AptarGroup, Inc. (NYSE:ATR)

Relative Strength Index (RSI): 35.12 

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing technologies, highlighted its growth strategy and long-term outlook during its Investor Day on September 9, 2025. Executive presentations emphasized strong momentum in the Pharma segment, driven by rising demand for innovative biologics, injectables, and patient-friendly drug delivery solutions.

In Q2 2025, AptarGroup, Inc. (NYSE:ATR) reported a 6% increase in revenue compared to the prior year, with net income rising 24% to $112 million and adjusted EBITDA up 13%. Earnings per share grew 25%, reflecting operational efficiencies and strong demand across the Pharma and Closures segments.

The company signaled confidence in its sustained performance by announcing a nearly 7% increase in its quarterly dividend to $0.48 per share, marking 32 consecutive years of dividend growth. AptarGroup, Inc. (NYSE:ATR) also returned $100 million to shareholders in dividends and share repurchases during the second quarter, totaling $210 million for the first half of the year, demonstrating a shareholder-friendly capital allocation approach.

11. Danaher Corporation (NYSE:DHR)

Relative Strength Index (RSI): 34.98 

Danaher Corporation (NYSE:DHR), a global leader in life sciences and diagnostics, continues to advance its bioprocessing, diagnostics, and life sciences segments through innovation and strategic partnerships. In Q2 2025, the company marked its eighth consecutive quarter of increased orders in bioprocessing, driven by strong demand for consumables from major pharmaceutical clients. The biotechnology segment saw a 6% year-over-year revenue rise, supported by growing monoclonal antibody demand, while molecular diagnostics contributed to a 2% core revenue increase, led by Beckman Coulter Diagnostics.

Strategic acquisitions have further strengthened Danaher Corporation (NYSE:DHR)’s portfolio. The December 2023 acquisition of Abcam, known for its antibody products, added to Life Sciences segment revenue, reflecting the business’s focus on innovation and diversification. Additionally, the firm is advancing precision medicine through a partnership with AstraZeneca to develop next-generation AI-powered diagnostics, aiming to scale precision healthcare and streamline diagnostic development. As one of the most oversold stocks in the sector, DHR continues to attract attention for its resilience and strategic growth moves.

Danaher Corporation (NYSE:DHR) maintains a shareholder-friendly approach, raising its quarterly dividend by 18.5% to 32 cents per share in early 2025, signaling confidence amid mixed market demand in academic, government, and energy filtration sectors.

10. Inspire Medical Systems, Inc. (NYSE:INSP)

Relative Strength Index (RSI): 34.57 

Inspire Medical Systems, Inc. (NYSE:INSP), a leader in minimally invasive devices for obstructive sleep apnea (OSA), reported challenges in the commercial rollout of its new Inspire V system. Delays in onboarding treatment centers and navigating reimbursement processes have slowed full patient adoption, with some patients still using the older Inspire IV model, impacting revenue growth in 2025.

Inspire Medical Systems, Inc. (NYSE:INSP) also faces increasing competition from GLP-1 drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, which are FDA-approved for weight management and OSA treatment. These medications, widely marketed directly to consumers, are reducing demand for implantable devices like INSP’s. In response, Inspire revised its 2025 sales forecast to a range of $900–$910 million. CEO Tim Herbert noted that the slower U.S. commercial launch and extended transition to Inspire V will weigh on annual financial performance.

Despite these challenges, Inspire Medical Systems, Inc. (NYSE:INSP)’s Board authorized a $200 million share buyback plan in August 2025, signaling confidence in the company’s long-term prospects. The firm expects a marketing push and expansion of treatment centers in the second half of 2025, which could boost procedure volumes and revenue growth into 2026. Additionally, CFO Rick Buchholz announced plans to depart at year-end, moving into an advisory role to facilitate a smooth leadership transition.

9. Integer Holdings Corporation (NYSE:ITGR)

Relative Strength Index (RSI): 34.11 

Integer Holdings Corporation (NYSE:ITGR), a global contract development and manufacturing organization specializing in medical devices, reported solid growth in 2025. Q2 sales rose 11% to $476 million, driven by new product launches in the electrophysiology and neurovascular markets. The Cardio & Vascular segment led the surge with 24% growth, while the Cardiac Rhythm & Neuromodulation segment saw modest gains despite a continued exit from portable medical products.

Integer Holdings Corporation (NYSE:ITGR) continues to innovate with advanced technologies, including VSiarylene coating for electrophysiology devices, enhancing performance and longevity. These innovations underscore Integer’s focus on high-growth niches and its commitment to collaborating with OEMs on cutting-edge solutions. Considered one of the most oversold stocks in the healthcare space, the company has still managed to draw investor optimism through steady innovation and strategic partnerships

A leadership transition is set for October 2025, as CEO Joseph Dziedzic retires and COO Payman Khales assumes the top role. The change is expected to support ongoing strategic growth initiatives and strengthen the company’s market position.

Despite recent sales momentum, Integer Holdings Corporation (NYSE:ITGR)’s stock hit a 52-week low in September 2025, trading just above $103. Analysts maintain broadly positive outlooks, with an average target price near $140, reflecting confidence in future growth driven by product innovation and market expansion.

8. Summit Therapeutics Inc. (NASDAQ:SMMT)

Relative Strength Index (RSI): 33.95 

Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cell lung cancer (NSCLC), has made significant strides with its lead investigational drug, ivonescimab. The HARMONi Phase III trial for EGFR-mutated NSCLC patients demonstrated a statistically significant improvement in progression-free survival when ivonescimab was combined with platinum-based chemotherapy versus placebo. While overall survival trends were positive, they did not reach statistical significance.

Summit Therapeutics Inc. (NASDAQ:SMMT) recently received approval in China for ivonescimab as a first-line treatment for PD-L1-positive advanced NSCLC, reflecting geographic expansion. Patient enrollment is ongoing in global Phase III trials, including the newly initiated U.S. cohorts, highlighting continued momentum in clinical development.

Despite these advances, the business’s stock has faced volatility in 2025. Investor concerns have arisen from mixed trial outcomes in North America and Europe compared to stronger results in China, raising questions about broader commercial potential. Additionally, Summit Therapeutics Inc. (NASDAQ:SMMT) is navigating legal scrutiny from a securities fraud lawsuit tied to the Pinnacle Study.

7. Glaukos Corporation (NYSE:GKOS)

Relative Strength Index (RSI): 33.64 

Glaukos Corporation (NYSE:GKOS), a leader in ophthalmic pharmaceutical and surgical therapies, continues to expand its presence in glaucoma, corneal disorders, and retinal diseases through innovative “dropless” treatment platforms. Its FDA-approved iDose sustained-release implant delivers continuous glaucoma therapy directly inside the eye, improving patient adherence and outcomes.

In 2025, the company reported robust growth, with Q2 net sales up 30% year-over-year to $124.1 million. U.S. glaucoma treatment sales reached $72.3 million in the quarter, prompting the company to raise full-year guidance to $480-$486 million. This growth reflects strong adoption of the iDose TR implant and increasing market penetration. Despite being listed among the most oversold stocks recently, GKOS has continued to deliver strong operational performance

Glaukos Corporation (NYSE:GKOS) is also advancing its pipeline with next-generation therapies. The iDose TREX implant, in Phase 2b/3 trials, aims to extend treatment duration and improve compliance, while ongoing trials for iStent Infinite and PRESERFLO devices broaden the business’s long-term growth potential.

Glaukos Corporation (NYSE:GKOS)’s Epioxa, a non-invasive epi-on corneal cross-linking therapy for keratoconus, received FDA acceptance for review with a PDUFA date of October 20, 2025. If approved, it would be the first therapy of its kind not requiring corneal epithelium removal, offering shorter recovery times and enhanced patient comfort.

6. Qiagen N.V. (NYSE:QGEN)

Relative Strength Index (RSI): 33.23 

Qiagen N.V. (NYSE:QGEN), a global leader in molecular diagnostics and sample preparation, continues to expand its precision medicine footprint through innovative testing solutions for infectious diseases, cancer genomic profiling, and cell and gene therapy quality control.

In Q2 2025, the business reported 7% net sales growth year-over-year, driven by strong adoption of key products such as QIAstat-Dx and QuantiFERON. The company plans to launch three new instruments starting in late 2025, aiming to enhance diagnostic capabilities and support future growth.

Qiagen N.V. (NYSE:QGEN) has also advanced its precision oncology portfolio with new QIAseq panels that enable fast, comprehensive cancer genomic profiling, reducing hands-on time and improving cost-effectiveness for laboratories. Additional innovations include the QIAseqHYB Read Panels for long-read sequencing, which address complex genomic regions and support a wide range of next-generation sequencing platforms.

A major milestone in 2025 is the FDA clearance and commercial rollout of QIAstat-Dx Rise, expected to expand diagnostic access and testing capacity, particularly in the U.S. healthcare market. These developments reinforce Qiagen N.V. (NYSE:QGEN)’s strategy of strengthening its molecular diagnostics offerings and expanding its role in precision medicine and biotherapeutic development.

5. Telix Pharmaceuticals Limited (NASDAQ:TLX)

Relative Strength Index (RSI): 33.19 

Melbourne-based Telix Pharmaceuticals Limited (NASDAQ:TLX) is advancing its global footprint in precision oncology and targeted radiotherapies, with active clinical programs in prostate cancer and rare oncologic conditions.

In its 2025 half-year update, the company reported a 30% revenue increase in its Precision Medicine segment, led by strong demand for its flagship PET imaging agent, Illuccix, and the launch of new products, including Gozellix, Zircaix, and Pixclara, across international markets. Telix Pharmaceuticals Limited (NASDAQ:TLX) has also expanded its manufacturing capabilities through Telix Manufacturing Solutions, supporting clinical and commercial operations worldwide.

Despite being featured among the most oversold stocks in recent months, the corporation continues to invest heavily in its therapeutics pipeline, increasing R&D spending by 47% year-over-year to $81.6 million. Key milestones include completion of target enrollment for the Phase 3 TLX591 trial in advanced metastatic castration-resistant prostate cancer (mCRPC), initiation of a Phase 1 first-in-human trial for TLX592, and the start of the pivotal IPAX BrIGHT trial for TLX101 in metastatic brain cancer. Additionally, the company gained IND approval for a Phase 1 study of TLX090 to manage bone pain in osteoblastic metastatic disease.

Diagnostic growth is further supported by the dosing of the first patient in the pivotal Phase 3 BiPASS trial, aimed at expanding indications for Illuccix and Gozellix in prostate cancer imaging. These developments highlight Telix Pharmaceuticals Limited (NASDAQ:TLX)’s dual strategy of commercial expansion and clinical innovation, positioning the company as a leader in radiopharmaceuticals and precision oncology globally.

4. Prestige Consumer Healthcare Inc. (NYSE:PBH)

Relative Strength Index (RSI): 32.08 

Prestige Consumer Healthcare Inc. (NYSE:PBH), a global developer of OTC health and personal care products, is taking strategic steps to secure growth in its eye care business amid operational challenges in 2025.

In August 2025, Prestige Consumer Healthcare Inc. (NYSE:PBH) acquired Pillar5 Pharma, a key supplier of multi-dose sterile ophthalmic products, including those for its Clear Eyes brand. The acquisition aims to address previous supply constraints that limited shipments and revenue, ensuring reliable production and supporting long-term expansion in the eye care segment. The firm expects supply improvements to accelerate in the second half of 2025, reversing earlier declines.

Despite a 6.6% year-over-year revenue decline in Q1 2026, Prestige Consumer Healthcare Inc. (NYSE:PBH) reported momentum across other business segments, including international OTC healthcare growth and improved gross margins. CEO Ron Lombardi emphasized that integrating Pillar5’s capabilities strengthens the Clear Eyes franchise and overall business resilience.

3. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Relative Strength Index (RSI): 30.42 

Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics, continues to advance its product portfolio and market presence in 2025.

A key growth driver is its droplet digital PCR (ddPCR) platform, led by the QX600 system. The company recently acquired Stilla Technologies to enhance ddPCR capabilities and enter new molecular testing markets. New instrument launches, including the QX Series dd instruments and QX Continuum, are simplifying workflows and offering greater flexibility, with mid-single-digit revenue growth expected in 2025.

Despite being listed among the most oversold stocks, Bio-Rad Laboratories, Inc. (NYSE:BIO) also launched several products to strengthen its diagnostics and research offerings. These include the EZ-Check Salmonella spp. Kit, approved by AOAC International, StarBright dyes for spectral flow cytometry, and the XP-Design Assay Salmonella Serotyping solution, which provides rapid and accurate food safety testing.

In bioprocess chromatography, the corporation expanded its offerings with Nuvia wPrime 2A media for scalable biomolecule purification and extended Foresight Pro prepacked columns for GMP-ready biotherapeutic production. These innovations support both small- and large-scale research and manufacturing workflows.

While challenges remain in the U.S. academic and government sectors, Bio-Rad Laboratories, Inc. (NYSE:BIO) is seeing improved performance in international markets, including Japan and Korea. At the Wells Fargo Healthcare Conference in September 2025, the company highlighted strong Q2 results driven by chromatography and consumables, with a capital markets day planned for spring 2026 to outline further growth strategies.

2. Haemonetics Corporation (NYSE:HAE)

Relative Strength Index (RSI): 29.99 

Haemonetics Corporation (NYSE:HAE), a global leader in blood and plasma management technologies, continues to advance healthcare efficiency through innovative medical devices.

In 2025, the company launched the PerQseal Elite vascular closure system, receiving European CE Mark approval. This fully bioresorbable, sutureless device is designed for large-bore vascular access sites commonly used in procedures such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). The PerQseal Elite deploys from inside the vessel without leaving residual materials like collagen or metal implants, restoring the vessel to its natural state while improving procedural control. This launch highlights the industry trend toward minimally invasive, bioresorbable devices that enhance patient outcomes and procedural efficiency.

Haemonetics Corporation (NYSE:HAE) released its first-quarter fiscal 2026 results on August 7, 2025. The business reported an earnings per share (EPS) of $1.10, beating analyst estimates by $0.09, while revenue declined 4.4% year-over-year to $321.39 million. Despite the revenue dip, the business demonstrated resilience in profitability and operational performance, highlighting its ability to navigate challenging market conditions.

In early 2025, Haemonetics Corporation (NYSE:HAE) reinforced its leadership team with strategic appointments. Frank Chan, Ph.D., was named Executive Vice President and Chief Operating Officer, overseeing research and development, regulatory affairs, manufacturing, and supply chain. Roy Galvin was appointed Executive Vice President and Chief Commercial Officer, leading global commercialization initiatives. These changes reflect the company’s focus on strengthening operational excellence and expanding its commercial reach.

1. Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Relative Strength Index (RSI): 25.03 

Soleno Therapeutics, Inc. (NASDAQ:SLNO) tops our list for being one of the most oversold stocks. It is a clinical-stage biotech focused on rare diseases and has seen significant stock volatility in 2025 following the commercial launch of its lead product, VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (PWS). The therapy addresses extreme hunger and metabolic challenges in PWS patients and represents a key step in the company’s rare disease portfolio.

The stock experienced a sharp decline in mid-August after a short-seller report raised safety concerns about VYKAT XR, triggering a selloff of over 10% in two trading days and a subsequent securities class action investigation. Despite this, the drug has gained early traction, with 646 patient initiations from 295 prescribers covering more than 100 million U.S. lives. Soleno Therapeutics, Inc. (NASDAQ:SLNO) is also pursuing European approval through the EMA, signaling its strategy for international market expansion.

Market reaction has left the business among the most oversold healthcare stocks of 2025, with the stock losing roughly 26% in a month. However, technical indicators suggest the selling pressure may be nearing exhaustion. Analysts remain optimistic, maintaining buy ratings with average price targets of $110–$120, reflecting confidence in the firm’s long-term commercial potential.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) continues to focus on raising awareness of VYKAT XR through clinical data presentations and targeted commercialization efforts, aiming to secure a solid foothold in the PWS treatment market despite short-term headwinds.

While we acknowledge the potential of SLNO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLNO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.